stoxline Quote Chart Rank Option Currency Glossary
  
Annovis Bio, Inc. (ANVS)
11.9  -0.13 (-1.08%)    03-28 16:00
Open: 12
High: 12.575
Volume: 248,865
  
Pre. Close: 12.03
Low: 11.58
Market Cap: 127(M)
Technical analysis
2024-03-28 4:49:41 PM
Short term     
Mid term     
Targets 6-month :  15.48 1-year :  18.08
Resists First :  13.26 Second :  15.48
Pivot price 10.3
Supports First :  10.07 Second :  8.1
MAs MA(5) :  11.78 MA(20) :  9.98
MA(100) :  10.3 MA(250) :  11.58
MACD MACD :  0.5 Signal :  0.1
%K %D K(14,3) :  69.8 D(3) :  68
RSI RSI(14): 61.9
52-week High :  22.48 Low :  5.42
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ANVS ] has closed below upper band by 19.8%. Bollinger Bands are 0.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 12.6 - 12.67 12.67 - 12.72
Low: 11.42 - 11.5 11.5 - 11.56
Close: 11.79 - 11.91 11.91 - 12.01
Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Headline News

Tue, 26 Mar 2024
Is Annovis Bio Inc (ANVS) Stock a Bad Value Tuesday? - InvestorsObserver

Thu, 21 Mar 2024
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet - Yahoo Finance

Thu, 21 Mar 2024
Premarket Mover: Annovis Bio Inc (ANVS) Down 3.33% - InvestorsObserver

Wed, 20 Mar 2024
Is Annovis Bio Inc (ANVS) Stock About to Get Hot Wednesday? - InvestorsObserver

Wed, 20 Mar 2024
Annovis Bio Promises Market-Impacting Information Release - TipRanks.com - TipRanks

Wed, 20 Mar 2024
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 11 (M)
Shares Float 8 (M)
Held by Insiders 24.5 (%)
Held by Institutions 11.5 (%)
Shares Short 1,470 (K)
Shares Short P.Month 1,310 (K)
Stock Financials
EPS -4.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.74
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -124.1 %
Return on Equity (ttm) -227.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -34 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -2.46
PEG Ratio 0
Price to Book value 16.08
Price to Sales 0
Price to Cash Flow -3.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android